Hjem › Ikke-småcellet lungekreft › Texas › Irving
Kliniske studier for Ikke-småcellet lungekreft i Irving, TX
22 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Irving (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #73, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RekruttererFase 1
- NEXT Dallas, Irving
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- US Oncology Investigational Product Center (IPC), Irving
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center(IPC), Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RekruttererFase 3
- US Oncology Research Investigational Products Center, Irving
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RekruttererFase 1/2
- US Oncology Investigational Products Center (IPC), Irving
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
- NEXT Oncology - Irving, Irving
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RekruttererFase 1/2
- Next Oncology - Dallas, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- NEXT Dallas, Irving
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruttererFase 2/3
- Local Institution - 007-999, Irving
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekruttererFase 1/2
- Next Oncology Dallas, Irving
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RekruttererFase 1/2
- NEXT Dallas - Oncology Department, Irving
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
RekruttererFase 1/2
- NEXT Dallas, Irving
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RekruttererFase 1
- NEXT Dallas, Irving
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- US Oncology Investigational Product Center (IPC), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekruttererFase 1/2
- NEXT Oncology Dallas, Irving
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- Next Oncology Dallas /ID# 276254, Irving
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekruttererFase 1
- NEXT Texas LLC - Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RekruttererFase 1
- NEXT Oncology Dallas, Irving
A 2-part Phase 1/2 Open-label Trial on ODM-212
RekruttererFase 1/2
- NEXT Oncology, Irving
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RekruttererFase 1/2
- NEXT, Dallas, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RekruttererFase 1/2
- NEXT Dallas, Irving
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Irving
- Kreft (alle typer)15 studier
- Kolorektal kreft13 studier
- Metastatisk kreft11 studier
- Brystkreft7 studier
- Mavekreft7 studier
- Pankreaskreft7 studier
- Plateepitelcancer i hode og hals6 studier
- Småcellet lungekreft6 studier
- Lungekreft6 studier
- Eggstokkreft5 studier
- Endometriekreft4 studier
- Tripelnegativ brystkreft4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.